Literature DB >> 21710251

Iron deficiency in children with early chronic kidney disease.

Rossana Baracco1, Sermin Saadeh, Rudolph Valentini, Gaurav Kapur, Amrish Jain, Tej K Mattoo.   

Abstract

Iron deficiency (ID) contributes to the development of anemia in patients with chronic kidney disease (CKD). The frequency of ID in children with early CKD has not previously been reported. This was a retrospective chart review of children with CKD stages 2 and 3 followed at the CKD clinic of Children's Hospital of Michigan. ID was defined as low ferritin and transferrin saturation <20%. Patients on iron supplements were considered as iron-deficient cases. There were 50 patients included in the study (72% male) with a mean age of 10.31 (±5.21). The mean glomerular filtration rate (GFR) was 55.4 ml/min/1.73 m(2) (±14.61). ID was present in 42% of patients, out of whom almost half (42.9%) presented with anemia. Females had a higher frequency of ID (64.3%). The frequency of ID with anemia increased from 4.3% to 29.6%, (p = 0.03) in stage 2 to stage 3 CKD, respectively. The frequency of ID without anemia also increased with progression of CKD from stage 2 to stage 3, however, the difference was not statistically significant. ID is frequent in patients with early CKD. Monitoring of iron tests and treatment of ID is important in this population of patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21710251     DOI: 10.1007/s00467-011-1946-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  15 in total

1.  Effect of phosphate binders on supplemental iron absorption in healthy subjects.

Authors:  Maria C Pruchnicki; James D Coyle; Stacy Hoshaw-Woodard; William H Bay
Journal:  J Clin Pharmacol       Date:  2002-10       Impact factor: 3.126

2.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2006-05       Impact factor: 8.860

Review 3.  Considerations for optimal iron use for anemia due to chronic kidney disease.

Authors:  J Q Hudson; T J Comstock
Journal:  Clin Ther       Date:  2001-10       Impact factor: 3.393

4.  Prevalence of complications in children with chronic kidney disease according to KDOQI.

Authors:  H Wong; K Mylrea; J Feber; A Drukker; G Filler
Journal:  Kidney Int       Date:  2006-06-21       Impact factor: 10.612

5.  The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation.

Authors:  Gaël Nicolas; Caroline Chauvet; Lydie Viatte; Jean Louis Danan; Xavier Bigard; Isabelle Devaux; Carole Beaumont; Axel Kahn; Sophie Vaulont
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

6.  Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis.

Authors:  Jolanta Malyszko; Jacek S Malyszko; Krystyna Pawlak; Michal Mysliwiec
Journal:  Am J Hematol       Date:  2006-11       Impact factor: 10.047

7.  Iron deficiency and cognitive achievement among school-aged children and adolescents in the United States.

Authors:  J S Halterman; J M Kaczorowski; C A Aligne; P Auinger; P G Szilagyi
Journal:  Pediatrics       Date:  2001-06       Impact factor: 7.124

8.  Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004.

Authors:  Steven Fishbane; Simcha Pollack; Harold I Feldman; Marshall M Joffe
Journal:  Clin J Am Soc Nephrol       Date:  2008-11-05       Impact factor: 8.237

9.  Hemoglobin decline in children with chronic kidney disease: baseline results from the chronic kidney disease in children prospective cohort study.

Authors:  Jeffrey J Fadrowski; Christopher B Pierce; Stephen R Cole; Marva Moxey-Mims; Bradley A Warady; Susan L Furth
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 8.237

Review 10.  Iron deficiency: definition and diagnosis.

Authors:  J D Cook; B S Skikne
Journal:  J Intern Med       Date:  1989-11       Impact factor: 8.989

View more
  6 in total

1.  Restless Legs Syndrome in Chronic Kidney Disease: Is Iron or Inflammatory Status To Blame?

Authors:  Sandeep K Riar; Larry A Greenbaum; Donald L Bliwise; Roberta M Leu
Journal:  J Clin Sleep Med       Date:  2019-11-15       Impact factor: 4.062

2.  Association between common iron store markers and hemoglobin in children with chronic kidney disease.

Authors:  Meredith A Atkinson; Christopher B Pierce; Jeffrey J Fadrowski; Nadine M Benador; Colin T White; Martin A Turman; Cynthia G Pan; Alison G Abraham; Bradley A Warady; Susan L Furth
Journal:  Pediatr Nephrol       Date:  2012-07-27       Impact factor: 3.714

3.  Chronic kidney disease in children: A report from a tertiary care center over 11 years.

Authors:  Alaleh Gheissari; Saeedeh Hemmatzadeh; Alireza Merrikhi; Sharareh Fadaei Tehrani; Yahya Madihi
Journal:  J Nephropathol       Date:  2012-10-01

Review 4.  Oxidative stress in chronic kidney disease.

Authors:  Kristien Daenen; Asmin Andries; Djalila Mekahli; Ann Van Schepdael; François Jouret; Bert Bammens
Journal:  Pediatr Nephrol       Date:  2018-08-13       Impact factor: 3.714

Review 5.  Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease.

Authors:  Norishi Ueda; Kazuya Takasawa
Journal:  Nutrients       Date:  2018-08-27       Impact factor: 5.717

Review 6.  A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.

Authors:  Mark R Hanudel; Marciana L Laster; Anthony A Portale; Aditi Dokras; Raymond P Quigley; German A Lozano Guzman; Joshua J Zaritsky; Nicole A Hayde; Frederick J Kaskel; Mark M Mitsnefes; Jorge A Ramirez; Peace D Imani; Poyyapakkam R Srivaths; Amy J Kogon; Michelle R Denburg; Tom D Blydt-Hansen; Loretta Z Reyes; Larry A Greenbaum; Darcy K Weidemann; Bradley A Warady; David A Elashoff; Susan R Mendley; Tamara Isakova; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2022-03-02       Impact factor: 3.651

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.